hypothesis of 'the possibility that other and more subtle genetic instabilities may be associated with the schizophrenic disorders,' we hypothesized that X-chromosome anomalies may be associated with previously unidentified microdeletions and/or duplications that predispose to schizophrenia. To test this hypothesis, we completed whole genome high density SNP and comparative genomic hybridization (CGH) arrays to ascertain novel structural variants (see details in Walsh et al. 18 ). Briefly, Affymetrix Mapping 500K SNP arrays and Agilent 185K/244K oligo array CGH were completed according to manufacturer protocols (www.affymetrix.com, www. agilent.com) and only variants that were identified through both methods were considered for analysis. Results did not reveal any further de novo chromosomal events among the probands with X-chromosome anomalies that could be implicated in the etiology of schizophrenia. Nor did these cases tend to have a higher rate of rare structural variants as compared to karyotypically normal female COS probands (results not shown). However, the one case with atypical Turner's syndrome who was missing part of one Xq arm was found to have also a 17 Mb duplication of chromosome 16q22.2-ter. Spectral karyotyping revealed that the extra copy of this segment of chromosome 16 was attached to the missing arm of the X chromosome. The duplicated region of chromosome 16 contains approximately 100 known genes, but presents an interesting case as it is not clear what the functionality of the derived chromosome X;16 would be. It is conceivable that the entire chromosome would be subject to X-inactivation, though functional studies would be warranted for this case.
To summarize, this report confirms that subsyndromal sex chromosome anomalies in COS are significantly higher than that found in the community or in AOS. The role of these anomalies in schizophrenia is unclear, though dysregulation of emotional processing may be one component. Although we had hypothesized that these cases may have other, more subtle submicroscopic structural variants that could be involved in schizophrenia etiology, this was not confirmed. To date, the overall rate of large chromosomal abnormalities and 22q11 deletions among this COS cohort is 10%. Schizophrenia (MIM 181500) is a severe and common psychiatric disorder affecting B1% of the world population. As a leading cause of psychiatric admissions, schizophrenia accounts for a considerable portion of health-care expenditures and is viewed as a major public health concern.
1 Due to the complexity of schizophrenia, its genetic etiology is still unclear. 2 Structural variation or copy number variation (CNV) is widely distributed in human genome and accounts for more genomic differences than single nucleotide polymorphisms. 3, 4 Genomic rearrangements and gene copy-number alterations have already been considered as causes of nervous system disorders. 5 Recently, Walsh et al. 6 found that schizophrenia patients, especially young onset schizophrenia patients, carried extremely more gene-based microdeletions or microduplications (larger than 100 kb) than normal controls, and implicated a 'common disease-rare variant' assumption. To validate their finding, we carried out a genome-wide replication study of rare CNVs in Chinese Han sample set.
In this study, we recruited 155 cases (87 men and 68 women, mean onset age is 27.00 ± 8.91 years) and 187 controls (105 men and 81 women, mean age is 28.51±8.40 years). All the volunteers and their parents are Shanghai local residents. Subjects with schizophrenia were strictly diagnosed by two independent psychiatrists according to the criteria of DSM-IV. All patients had a consensus diagnosis of schizophrenia in independent interviews by two psychiatrists. Normal controls were chosen from random population. A standard informed consent in the protocol, which was reviewed and approved by the Shanghai Ethical Committee of Human Genetics Resources, was given by the participants after the nature of study had been fully explained.
Genome-wide scans for structural variants greater than 100 kb were carried out by comparative analysis of hybridization intensities on Affymetrix GeneChip Human Mapping 500K, following the manufacturer's protocol and a stringent quality control criteria. For those schizophrenia-gene-based rare CNVs (referring to the SchizophreniaGene Database, http://www.schizophreniaforum.org/res/sczgene/dbindex.asp), we chose realtime PCR method to validate the experimental results.
We analyzed the CNV data by software Partek Genomics Suite, trail version. HMM algorithm was used to detect CNVs with default parameters set by Partek.
In total, 93 CNVs larger than 100 kb were discovered, 82 were considered as rare CNVs with frequencies less than 1% and 59 rare CNVs impacted one or more genes. Among 155 schizophrenia patients, 109 (70.3%) had CNV, 33 (21.3%) had rare CNV and 22 (14.2%) harbored one or more rare structural variants that deleted or duplicated or disrupted genes; whereas among the 187 controls, 132 (70.6) had CNV, 44 (23.5) had rare CNV and 33 (17.6%) carried rare CNVs impacting genes (Table 1 ). There was no trend of difference of CNVs (P = 1.00), rare CNVs (P = 0.70) and rare CNVs affecting genes (P = 0.46) between cases and controls ( Table 1) .
For patients with onset age p18, 7 of 36 individuals carried rare CNVs, all of which were gene-related CNVs, no significant difference compared with normal controls (Table 1) .
To assess whether the functions of those genes impacted by CNVs could be related to schizophrenia, we searched the SchizophreniaGene database. In cases, five (5.2%) genes were supposed to be associated with schizophrenia; in controls, eight (2%) were supposed to be associated with schizophrenia (Table 2) . Moreover, among the five SchizophreniaGenes impacted in cases, three were in deleted state and two were in duplicated status; whereas among the eight SchizophreniaGenes affected in control, only one gene was deleted state and other seven were all in duplicated status (Table 2) . We carried out a genome-wide scan for structural variants greater than 100 kb on genomic DNA of 342 individuals. Our sample set included 155 schizophrenia patients and 187 normal controls. In Walsh et al.'s study, 150 cases and 268 controls were recruited for the main analysis. Thus, the sample size is close to each other, especially the case samples.
Unlike Walsh et al.'s study, we found no trend of significant difference of all CNVs (P = 1.00) or all rare CNVs (frequency < 1%, P = 0.70) or rare CNVs affecting genes (P = 0.46) between cases and controls. In our 155 cases, 22 carried rare CNVs deleting or duplicating or disrupting genes, whereas 38 of 150 patients carried gene-related rare CNVs in Walsh et al.'s study; in our 36 patients with onset age not more than 18, only 5 carried gene-related rare CNVs, whereas 25 of 76 such patients had gene-related rare CNVs in Walsh et al.'s study. Obviously, our cases tended to have less gene-related CNVs than the previous study.
Referring to the SchizophreniaGene Database, we studied the distribution of rare CNVs affecting schizophrenia susceptibility genes. We found that 5 of 96 genes impacted by rare CNVs were SchizophreniaGenes in cases (5.2%), whereas 8 of 399 genes affected by rare CNVs were SchizophreniaGenes in controls (2.0%). Moreover, three of those five genes in cases were in deleted status, and only one of eight genes in controls was in deleted status. Given that the deleted status could have more effect on gene function, much larger sample size should be used to replicate this trend of difference.
However, our results do not support Walsh et al.'s main finding that rare CNVs deleting, duplicating or disrupting genes happens more frequently in schizophrenia patients, especially schizophrenia patients with small onset ages (onset age p18 in their study). Though different population might have genetic heterogeneity of disease etiologies, we need to be more prudently to decide whether rare CNVs play a big role in schizophrenia etiology. Much larger number of samples were suggested to study such low frequency variants in the future. 2 ), including cardiovascular disease. [3] [4] [5] Development of animal models is required to understand the specific physiological mechanisms responsible for the effects of social isolation on health. Here, we provide evidence that social isolation in mice potentiates the pathophysiological responses to cardiac arrest (CA), which may explain, in part, why social isolation is as strong a predictor of 1-year mortality among acute myocardial infarction patients as some of the classic physiological risk factors, including high blood cholesterol concentrations and hypertension. 5 To determine the impact of social environment on neuroinflammation, neuronal death and corticosteroid concentrations after global ischemia, we housed adult male C3H/e mice either alone (isolated, n = 7) or five per cage (social, n = 5) beginning 2 weeks prior to
